FDA OKs Merck's diabetes drug combo Janumet

Gaining an edge in the race to introduce a new class of DPP-4 inhibitors for type 2 diabetes, the FDA gave Merck a green light to start selling a pill that combines a generic metformin with its newly approved Januvia. The combo, called Janumet, gives Merck an added edge over Novartis, which has been making the case for Galvus in the U.S. and Europe. Janumet will quickly hit the market with the message that the combo offers a more convenient therapy for diabetic patients in need of multiple drugs.

- read the release on the approval
- here's the report on the decision from TheStreet.com

ALSO: Shares of Cephalon were on the rise in premarket trading this morning as analysts responded to the news that the FDA had issued another "approvable" letter for its sleep drug Nuvigil. The letter includes conditions that the company will have to meet before full approval is given. The FDA asked for additional data that had been collected and will require prominent safety warnings. Report

PLUS: The FDA approved Baxter International's Ceprotin, a drug designed to treat a rare blood disorder in newborns. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.